DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non-Cystic Fibrosis Bronchiectasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Non-Cystic Fibrosis Bronchiectasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Cystic Fibrosis Bronchiectasis Market Forecast
Some of the key facts of the Non-Cystic Fibrosis Bronchiectasis Market Report:
• The Non-Cystic Fibrosis Bronchiectasis market size was valued approximately USD 1,718 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, the overall number of identified prevalent cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) across the 7 major markets (7MM) amounted to roughly 1,349,457 cases. Projections suggest an anticipated rise in these numbers by 2032 at a compound annual growth rate (CAGR) of 0.3% throughout the study duration (2019 to 2032).
• In 2022, the United States contributed to almost 27% of the total identified prevalent cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) among the 7 major markets (7MM). Projections indicate an anticipated increase in this percentage by the year 2032.
• In the United States, there were an estimated 85,811 cases of mild, 151,734 cases of moderate, and 130,742 cases of severe Non-Cystic Fibrosis Bronchiectasis (NCFB) in 2022. These numbers are projected to rise by the year 2032.
• In 2022, there were roughly 231,259 reported cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) among males in EU4 and the UK, while the female population accounted for nearly 260,860 cases. These figures are anticipated to rise by the year 2032.
• The pipeline for Non-Cystic Fibrosis Bronchiectasis (NCFB) treatments is relatively limited, including medications like Brensocatib, Colistimethate sodium, and several others anticipated to be introduced within the projected period from 2023 to 2032.
• Key Non-Cystic Fibrosis Bronchiectasis Companies: Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• The Non-Cystic Fibrosis Bronchiectasis epidemiology based on gender analyzed that in the US, females diagnosed with NCFB are higher in number than males.
• The Non-Cystic Fibrosis Bronchiectasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Cystic Fibrosis Bronchiectasis pipeline products will significantly revolutionize the Non-Cystic Fibrosis Bronchiectasis market dynamics.
Non-Cystic Fibrosis Bronchiectasis Overview
Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic respiratory condition characterized by the abnormal widening and thickening of the airways (bronchi) in the lungs. This condition leads to the accumulation of mucus and makes it difficult for the affected individual to clear the mucus from their airways, resulting in recurrent respiratory symptoms and frequent lung infections.
Get a Free sample for the Non-Cystic Fibrosis Bronchiectasis Market Forecast, Size & Share Analysis Report:
www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Cystic Fibrosis Bronchiectasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation:
The Non-Cystic Fibrosis Bronchiectasis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis by severity
• Gender-specific Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Diagnosed Cases of Episodic and Chronic Non-Cystic Fibrosis Bronchiectasis
Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast
www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Cystic Fibrosis Bronchiectasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Cystic Fibrosis Bronchiectasis market or expected to get launched during the study period. The analysis covers Non-Cystic Fibrosis Bronchiectasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Non-Cystic Fibrosis Bronchiectasis Therapies and Key Companies
• Brensocatib: Insmed/ AstraZeneca
• Colistimethatesodium: Zambion
• Trikafta: The Marcus Foundation, Inc.
• CHF 6333: Chiesi Farmaceutici S.p.A.
• S-1226: SolAeroMed Inc.
• CMS: Zambon SpA
• BI 1323495: Boehringer Ingelheim
• ARINA-1: Renovion, Inc.
• TIP: Novartis
• ALX-009: Alaxia SAS
Discover more about therapies set to grab major Non-Cystic Fibrosis Bronchiectasis market share @ Non-Cystic Fibrosis Bronchiectasis Treatment Landscape
www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Cystic Fibrosis Bronchiectasis Market Strengths
• Increasing disease prevalence due to better detection rate with advanced imaging techniques and improved awareness.
• An improved understanding of disease pathophysiology has improved diagnosis and is useful in determining novel target molecules for treatment development.
Non-Cystic Fibrosis Bronchiectasis Market Opportunities
• Large, positive, randomized controlled trials are necessary to set the standard of care for bronchiectasis patients.
• Vaccines and monoclonal antibodies, though partially useful, there is a need for evidence-based studies to use for the prevention of PA chronic colonization in bronchiectasis patients.
Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Cystic Fibrosis Bronchiectasis Companies: Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Cystic Fibrosis Bronchiectasis Unmet Needs, KOL's views, Analyst's views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement
To know more about Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market, visit @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Therapeutic Assessment
www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Market Report Introduction
2. Executive Summary for Non-Cystic Fibrosis Bronchiectasis
3. SWOT analysis of Non-Cystic Fibrosis Bronchiectasis
4. Non-Cystic Fibrosis Bronchiectasis Patient Share (%) Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
6. Non-Cystic Fibrosis Bronchiectasis Disease Background and Overview
7. Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Cystic Fibrosis Bronchiectasis
9. Non-Cystic Fibrosis Bronchiectasis Current Treatment and Medical Practices
10. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
11. Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
12. Non-Cystic Fibrosis Bronchiectasis Market Outlook
13. Country-Wise Non-Cystic Fibrosis Bronchiectasis Market Analysis (2019-2032)
14. Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement of Therapies
15. Non-Cystic Fibrosis Bronchiectasis Market Drivers
16. Non-Cystic Fibrosis Bronchiectasis Market Barriers
17. Non-Cystic Fibrosis Bronchiectasis Appendix
18. Non-Cystic Fibrosis Bronchiectasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Non-Cystic Fibrosis Bronchiectasis Pipeline www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Cystic Fibrosis Bronchiectasis market. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided, which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines.
Non-Cystic Fibrosis Bronchiectasis Epidemiology www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Cystic Fibrosis Bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Lung Transplant Rejection Market www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.
CAR T-Cell Therapy for Multiple Myeloma Market
www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Insulin Resistance Market
www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dyskinesia Market
www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hemophilia Market
www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Paroxysmal Nocturnal Hemoglobinuria Market
www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: [email protected]
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
